<DOC>
	<DOCNO>NCT00308464</DOCNO>
	<brief_summary>The purpose study explore safety , toleration dose response PHA-794428 multiple weekly injection male female growth hormone deficient patient .</brief_summary>
	<brief_title>A Study To Evaluate The Dose Response And Safety Of PHA-794428 In Adults With Growth Hormone Deficiency</brief_title>
	<detailed_description>The study terminate 10-Dec-2007 . Pfizer 's decision terminate program due case injection-site lipoatrophy report clinical Phase 2 study single injection PHA 794428 .</detailed_description>
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Male female patient severe AGHD . Hypopituitary patient must adequate hormone replacement therapy least 6 month . AGHD patient uncontrolled pituitary tumor growth . Tumors within 3 mm optic chiasm . Patients diabetes mellitus .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>